GlassScriptPhysician profile
Leila Saadatpour
NPI 1801384136
$7,143.09
in general payments reported to CMS, 2019-2025
11 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,510 · 2023: $2,025 · 2024: $1,786 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,272 · Food and Beverage: $2,258 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,271.62 |
| Food and Beverage | $2,258.09 |
| Education | $103.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,006.19 | 2022-2025 | Percept PC Brainsense |
| Abbott Laboratories | $1,702.70 | 2024-2025 | Infinity, Proclaim |
| Boston Scientific Corporation | $1,145.95 | 2023 | Vercise |
| Abbvie INC. | $385.03 | 2022-2025 | Botox |
| Teva Pharmaceuticals USA, INC. | $350.89 | 2022-2025 | Austedo Xr |
| Insightec,INC | $145.84 | 2025 | Exablate |
| Acorda Therapeutics, INC | $127.53 | 2023 | Inbrija |
| Amneal Pharmaceuticals LLC | $125.94 | 2023-2025 | Crexont |
| Alexion Pharmaceuticals, INC. | $75.00 | 2022 | |
| Acadia Pharmaceuticals INC | $64.17 | 2023 | Nuplazid |
| Neurocrine Biosciences, INC. | $13.85 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Saadatpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.